BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F December 3, 2017 SDAQ: HOLD HOLD RATING SINCE 03/02/2017 BUSINESS DESCRIPTION Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. STOCK PERFORMANCE (%) 3 Mo. 1 Yr. 3 Yr (Ann) Price Change 15.01 107.48 1.08 GROWTH (%) Last Qtr 12 Mo. 3 Yr CAGR Revenues 7.15 4.85 1.74 Net Income 6,858.33 10.98-8.69 EPS 5,850.00 17.32-5.76 RETURN ON EQUITY (%) Ind Avg S&P 500 Q1 2018 11.95 22.92 13.41 Q1 2017 12.75 25.46 11.79 Q1 2016 13.75 23.77 12.91 P/E COMPARISON Sector: Health Care Sub-Industry: Biotechnology Source: S&P Weekly Price: (US$) SMA (50) SMA (100) 1 Year 2 Years Rating History BUY HOLD SELL HOLD Volume in Millions 2016 2017 COMPUSTAT for Price and Volume, TheStreet Ratings, Inc. for Rating History 45 40 35 30 25 20 15 40 20 0 23.24 EPS ALYSIS¹ ($) 33.87 Ind Avg 25.45 S&P 500 RECOMMENDATION We rate () a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing nesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. HIGHLIGHTS 's revenue growth has slightly outpaced the industry average of 0.2%. Since the same quarter one year prior, revenues slightly increased by 7.2%. Growth in the company's revenue appears to have helped boost the earnings per share. Q1 0.42 Q2 0.50 Q3 0.47 2016 Q4 0.32 Q1-0.02 Q2 0.09 Q3 0.06 2017 = not available NM = not meaningful Q4 0.19 Q1 1.15 2018 1 Compustat fiscal year convention is used for all fundamental data items. 's debt-to-equity ratio is very low at 0.09 and is currently below that of the industry average, implying that there has been very successful management of debt levels. To add to this, has a quick ratio of 1.93, which demonstrates the ability of the company to cover short-term liquidity needs. The gross profit margin for is currently very high, coming in at 79.44%. Regardless of 's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, 's net profit margin of 42.63% significantly outperformed against the industry. reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, MYRIAD GENETICS INC reported lower earnings of $0.32 versus $1.71 in the prior year. This year, the market expects an improvement in earnings ($1.05 versus $0.32). The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor ness in the organization. In comparison to the other companies in the Biotechnology industry and the overall market, 's return on equity is significantly below that of the industry average and is below that of the S&P 500. PAGE 1
SDAQ: PEER GROUP ALYSIS REVENUE GROWTH AND EBITDA MARGIN* Revenue Growth (TTM) -200% 1200% UNFAVORABLE RARE -45000% EBITDA Margin (TTM) FOLD FAVORABLE BPMC LGND IRWD ARRY HALO CBPO ONCE OPK 5000% Companies with higher EBITDA margins and revenue growth rates are outperforming companies with lower EBITDA margins and revenue growth rates. Companies for this scatter plot have a market capitalization between $2.2 Billion and $2.9 Billion. Companies with or NM values do not appear. *EBITDA Earnings Before Interest, Taxes, Depreciation and Amortization. REVENUE GROWTH AND EARNINGS YIELD Revenue Growth (TTM) -200% 1200% FOLD UNFAVORABLE RARE -14% ONCE Earnings Yield (TTM) ARRY IRWD BPMC OPK HALO FAVORABLE LGND CBPO Companies that exhibit both a high earnings yield and high revenue growth are generally more attractive than companies with low revenue growth and low earnings yield. Companies for this scatter plot have revenue growth rates between -12.2% and 1076.9%. Companies with or NM values do not appear. 6% INDUSTRY ALYSIS The biotechnology industry employs biological and biochemical knowledge to develop, manufacture and trade products and processes for the diagnosis and treatment of diseases and ailments. It also develops genetically modified plant and animal species and food varieties. The industry has a noncyclical growth profile, which is insensitive to overall economic conditions. The industry focuses on specialty markets with primary sales and efforts targeted towards specialists such as hematologists, oncology physicians, rheumatologists and dermatologists. Consequently, the industry is highly reliant on research and development (R&D). US biotech companies dominating the market include larger players like Amgen (AMGN), Gilead (GILD) and Biogen (BIIB). Medical spending is expected to grow significantly in the coming quarters due to an aging population, increasing obesity and demand for quality treatment. Healthcare service providers have shown a willingness to incur higher costs to treat diseases and this supports margin expansion for successful treatments. US healthcare spending for the next decade is expected to be around $4.2 trillion or 20% of GDP. The biotechnology pipeline has become an important consideration for the pharmaceutical industry and its suppliers. The industry has witnessed an increase in financing and multi-billion-dollar mergers and acquisitions. R&D spending remains robust. The US continues to dominate in R&D spending, with approximately 81 cents of global expenditures being domestic. An average drug takes about 10 to 15 years from pre-clinical development to market approval. According to the FDA, for every 20 drugs that enter the clinical testing stage, only a few pass trial and gain approval. The traditional sales and profit metrics do not completely reveal the biotech companies otherwise lengthy, cost-intensive product-development periods. It is essential for investors to consider the number of products the biotech companies have in their pipeline, the time necessary for development and the potential market size of drugs. Patents held, effectiveness of these patents to protect market share, cash position, and current leverage position all impact biotech company outlook. Finally, R&D effectiveness, management competency and potential synergies from new or proposed M&A activities are important factors for investors to consider. PEER GROUP: Biotechnology Recent Market Price/ Net Sales Net Income Ticker Company Name Price ($) Cap ($M) Earnings TTM ($M) TTM ($M) 34.63 2,398 23.24 784.10 104.10 BPMC BLUEPRINT MEDICINES CORP 75.06 2,943 NM 27.49-120.36 OPK OPKO HEALTH INC 5.25 2,937 NM 1,149.29-108.63 LGND LIGAND PHARMACEUTICAL INC 131.85 2,783 191.09 128.82 16.44 ONCE SPARK THERAPEUTICS INC 73.23 2,710 NM 20.96-228.50 HALO HALOZYME THERAPEUTICS INC 18.67 2,658 NM 166.05-88.30 IRWD IRONWOOD PHARMACEUTICALS I 17.27 2,338 NM 291.53-142.53 FOLD AMICUS THERAPEUTICS INC 13.92 2,314 NM 25.03-273.44 CBPO CHI BIOLOGIC PRODUCTS HLDG 83.59 2,308 21.16 357.93 112.02 ARRY ARRAY BIOPHARMA INC 11.25 2,217 NM 141.33-126.20 RARE ULTRAGENYX PHARMACEUTICAL 50.49 2,150 NM 0.20-291.70 The peer group comparison is based on Major Biotechnology companies of comparable size. PAGE 2
SDAQ: COMPANY DESCRIPTION Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myrisk Hereditary Cancer, a D sequencing test for hereditary cancers; BRACAnalysis, a D sequencing test to assess the risk of developing breast and ovarian cancer; BART, a D sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a D sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a D sequencing test that is designed to be utilized to predict response to D damaging agents. It also provides COLARIS, a D sequencing test for colorectal and uterine cancer; COLARIS AP, a D sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a R expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a R expression test for assessing the aggressiveness of breast cancer. In addition, the company offers mypath Melanoma, a R expression test for diagnosing melanoma; mychoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency; and GeneSight, a D genotyping test to optimize psychotropic drug selection for neuroscience patients. Further, it provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah. 320 Wakara Way Salt Lake City, UT 84108 USA Phone: 801-584-3600 Fax: 801-584-3640 http://www.myriad.com STOCK-AT-A-GLANCE Below is a summary of the major fundamental and technical factors we consider when determining our overall recommendation of shares. It is provided in order to give you a deeper understanding of our rating methodology as well as to paint a more complete picture of a stock's strengths and nesses. It is important to note, however, that these factors only tell part of the story. To gain an even more comprehensive understanding of our stance on the stock, these factors must be assessed in combination with the stock s valuation. Please refer to our Valuation section on page 5 for further information. FACTOR SCORE Growth 2.0 out of 5 stars Measures the growth of both the company's income statement and cash flow. On this factor, has a growth score better than 30% of the stocks we rate. Total Return 2.5 out of 5 stars Measures the historical price movement of the stock. The stock performance of this company has beaten 40% of the companies we cover. Efficiency 4.5 out of 5 stars Measures the strength and historic growth of a company's return on invested capital. The company has generated more income per dollar of capital than 80% of the companies we review. Price volatility 2.0 out of 5 stars Measures the volatility of the company's stock price historically. The stock is less volatile than 30% of the stocks we monitor. Solvency 4.5 out of 5 stars Measures the solvency of the company based on several ratios. The company is more solvent than 80% of the companies we analyze. Income 0.5 out of 5 stars Measures dividend yield and payouts to shareholders. This company pays no dividends. THESTREET RATINGS RESEARCH METHODOLOGY TheStreet Ratings' stock model projects a stock's total return potential over a 12-month period including both price appreciation and dividends. Our Buy, Hold or Sell ratings designate how we expect these stocks to perform against a general benchmark of the equities market and interest rates. While our model is quantitative, it utilizes both subjective and objective elements. For instance, subjective elements include expected equities market returns, future interest rates, implied industry outlook and forecasted company earnings. Objective elements include volatility of past operating revenues, financial strength, and company cash flows. Our model gauges the relationship between risk and reward in several ways, including: the pricing drawdown as compared to potential profit volatility, i.e.how much one is willing to risk in order to earn profits; the level of acceptable volatility for highly performing stocks; the current valuation as compared to projected earnings growth; and the financial strength of the underlying company as compared to its stock's valuation as compared to projected earnings growth; and the financial strength of the underlying company as compared to its stock's performance. These and many more derived observations are then combined, ranked, weighted, and scenario-tested to create a more complete analysis. The result is a systematic and disciplined method of selecting stocks. PAGE 3
SDAQ: Consensus EPS Estimates² ($) IBES consensus estimates are provided by Thomson Financial FINCIAL ALYSIS 's gross profit margin for the first quarter of its fiscal year 2018 is essentially unchanged when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the industry, the net income growth has not. has liquidity. Currently, the Quick Ratio is 1.93 which shows the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow. Q2 FY17 1.05 E 2018(E) 1.15 E 2019(E) During the same period, stockholders' equity ("net worth") has increased by 18.40% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future. INCOME STATEMENT Net Sales ($mil) 190.20 177.50 EBITDA ($mil) 28.70 25.40 EBIT ($mil) 15.50 16.20 Net Income ($mil) 81.10-1.20 STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.thestreetratings.com. BALANCE SHEET Cash & Equiv. ($mil) 148.30 148.40 Total Assets ($mil) 1,228.30 1,270.90 Total Debt ($mil) 74.10 199.20 Equity ($mil) 870.90 735.50 PROFITABILITY Gross Profit Margin 79.44% 79.61% EBITDA Margin 15.08% 14.30% Operating Margin 8.15% 9.13% Sales Turnover 0.64 0.59 Return on Assets 8.47% 7.38% Return on Equity 11.95% 12.75% DEBT Current Ratio 2.34 1.17 Debt/Capital 0.08 0.21 Interest Expense 0.90 0.70 Interest Coverage 17.22 23.14 SHARE DATA Shares outstanding (mil) 69 68 Div / share 0.00 0.00 EPS 1.15-0.02 Book value / share 12.59 10.75 Institutional Own % Avg Daily Volume 946,558 1,074,799 2 Sum of quarterly figures may not match annual estimates due to use of median consensus estimates. PAGE 4
SDAQ: RATINGS HISTORY Our rating for has not changed since 3/2/2017. As of 11/30/2017, the stock was trading at a price of which is 7.2% below its 52-week high of $37.30 and 128.6% above its 52-week low of $15.15. 2 Year Chart BUY: $43.50 2016 HOLD: $20.80 SELL: $16.40 HOLD: $19.02 $50 $40 $30 $20 MOST RECENT RATINGS CHANGES Date Price Action From To 3/2/17 $19.02 Upgrade Sell Hold 11/2/16 $16.40 Downgrade Hold Sell 8/11/16 $20.80 Downgrade Buy Hold 11/30/15 $43.50 No Change Buy Buy Price reflects the closing price as of the date listed, if available RATINGS DEFINITIONS & DISTRIBUTION OF THESTREET RATINGS (as of 11/30/2017) 44.19% Buy - We believe that this stock has the opportunity to appreciate and produce a total return of more than 10% over the next 12 months. 30.85% Hold - We do not believe this stock offers conclusive evidence to warrant the purchase or sale of shares at this time and that its likelihood of positive total return is roughly in balance with the risk of loss. 24.96% Sell - We believe that this stock is likely to decline by more than 10% over the next 12 months, with the risk involved too great to compensate for any possible returns. TheStreet Ratings 14 Wall Street, 15th Floor New York, NY 10005 www.thestreet.com Research Contact: 212-321-5381 Sales Contact: 866-321-8726 VALUATION HOLD. The current P/E ratio indicates a significant discount compared to an average of 33.87 for the Biotechnology industry and a discount compared to the S&P 500 average of 25.45. To use another comparison, its price-to-book ratio of 2.75 indicates a discount versus the S&P 500 average of 3.24 and a significant discount versus the industry average of 17.57. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, proves to trade at a discount to investment alternatives within the industry. Price/Earnings 23.24 Peers 33.87 Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations. Price/Projected Earnings 30.11 Peers 18.83 Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations. is trading at a significant premium to its Price/Book 2.75 Peers 17.57 Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. Price/Sales 3.06 Peers 85.60 Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. industry on this measurement. DISCLAIMER: Price/CashFlow 17.90 Peers 32.24 Discount. The P/CF ratio, a stock s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. Price to Earnings/Growth 0.10 Peers 0.46 Discount. The PEG ratio is the stock s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. trades at a significant discount to its Earnings Growth lower higher 17.32 Peers 8.05 Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. is expected to have an earnings growth rate that significantly exceeds its Sales Growth lower higher 4.85 Peers 90.03 Lower. A sales growth rate that trails the industry implies that a company is losing market share. significantly trails its peers on the basis of sales growth The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but TheStreet Ratings cannot guarantee its accuracy and completeness, and that of the opinions based thereon. Data is provided via the COMPUSTAT Xpressfeed product from Standard &Poor's, a division of The McGraw-Hill Companies, Inc., as well as other third-party data providers. TheStreet Ratings is a division of TheStreet, Inc., which is a publisher. This research report contains opinions and is provided for informational purposes only. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional, before you make any investment. None of the information contained in this report constitutes, or is intended to constitute a recommendation by TheStreet Ratings of any particular security or trading strategy or a determination by TheStreet Ratings that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Your use of this report is governed by TheStreet, Inc.'s Terms of Use found at http://www.thestreet.com/static/about/terms-of-use.html. PAGE 5